Payment overview · 2025
General Payments
$1,818.08
84 reported records · 27 companies
Healthcare provider profile · identity verified
Subir Guha, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GALLATIN, TN · NPI 1104871029
Verified facts
What the public records show
CMS Open Payments records show Subir Guha, M.D. received $1,818.08 in general payments during 2025 across 84 reported records.
Corcept Therapeutics accounted for 9.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 258 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $180.21 | 9.9% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $174.13 | 9.6% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $162.02 | 8.9% | 11 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $144.57 | 8.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $134.78 | 7.4% | 10 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $134.44 | 7.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $100.24 | 5.5% | 5 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $84.90 | 4.7% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $80.97 | 4.5% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $73.22 | 4.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.87 | 3.5% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $58.84 | 3.2% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $58.72 | 3.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $52.86 | 2.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.81 | 2.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $39.35 | 2.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $31.57 | 1.7% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $26.57 | 1.5% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.48 | 1.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.73 | 1.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.46 | 1.1% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $19.86 | 1.1% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $19.71 | 1.1% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $18.97 | 1.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $18.72 | 1.0% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.47 | 1.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.61 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,775.58 | 83 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $180.21 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $162.02 | 11 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $144.57 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $144.57 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $144.57 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $134.78 | 10 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $134.44 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $133.72 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $129.98 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $116.31 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $90.27 | 4 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $84.90 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $80.97 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $73.22 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $58.84 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $58.72 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.27 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $52.86 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.15 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $43.97 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.97 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $39.81 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $39.35 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $31.57 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.09 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $26.57 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $26.57 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 258 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 256 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
38 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
256 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
258 | 62 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
40 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 940 | 292 |
| Lisinopril | Lisinopril | 644 | 186 |
| Amlodipine Besylate | Amlodipine Besylate | 583 | 182 |
| Gabapentin | Gabapentin | 488 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 424 | 128 |
| Losartan Potassium | Losartan Potassium | 424 | 135 |
| Omeprazole | Omeprazole | 407 | 143 |
| Trazodone Hcl | Trazodone Hcl | 405 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 369 | 105 |
| Tamsulosin Hcl | Tamsulosin Hcl | 366 | 107 |
| Furosemide | Furosemide | 354 | 114 |
| Potassium Chloride | Potassium Chloride | 351 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 346 | 123 |
| Metformin Hcl | Metformin Hcl | 335 | 93 |
| Finasteride | Finasteride | 286 | 85 |
| Metoprolol Tartrate | Metoprolol Tartrate | 274 | 91 |
| Meloxicam | Meloxicam | 271 | 95 |
| Ozempic | Semaglutide | 258 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 257 | 81 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 256 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 232 | 78 |
| Hydralazine Hcl | Hydralazine Hcl | 230 | 76 |
| Tizanidine Hcl | Tizanidine Hcl | 224 | 74 |
| Glimepiride | Glimepiride | 217 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 208 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 189 | 60 |
| Lovastatin | Lovastatin | 188 | 54 |
| Prednisone | Prednisone | 184 | 106 |
| Metformin Hcl Er | Metformin Hcl | 169 | 50 |
| Citalopram Hbr | Citalopram Hydrobromide | 168 | 51 |
| Carvedilol | Carvedilol | 157 | 54 |
| Allopurinol | Allopurinol | 154 | 46 |
| Alendronate Sodium | Alendronate Sodium | 150 | 51 |
| Simvastatin | Simvastatin | 138 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 49 |
| Doxycycline Hyclate | Doxycycline Hyclate | 128 | 103 |
| Sertraline Hcl | Sertraline Hcl | 122 | 36 |
| Famotidine | Famotidine | 114 | 43 |
| Ezetimibe | Ezetimibe | 112 | 35 |
| Montelukast Sodium | Montelukast Sodium | 112 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 108 | 39 |
| Nifedipine Er | Nifedipine | 107 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 30 |
| Buspirone Hcl | Buspirone Hcl | 101 | 37 |
| Azelastine Hcl | Azelastine Hcl | 100 | 57 |
| Eliquis | Apixaban | 99 | 28 |
| Jardiance | Empagliflozin | 99 | 23 |
| Ibuprofen | Ibuprofen | 96 | 40 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 95 | 77 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 92 | 21 |
| Bumetanide | Bumetanide | 90 | 31 |
| Alprazolam | Alprazolam | 85 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 27 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 75 | 34 |
| Pregabalin | Pregabalin | 73 | 18 |
| Clonazepam | Clonazepam | 72 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 20 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 69 | 25 |
| Nystatin | Nystatin | 69 | 40 |
| Chlorthalidone | Chlorthalidone | 66 | 21 |
| Xarelto | Rivaroxaban | 66 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 24 |
| Trulicity | Dulaglutide | 65 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 13 |
| Amoxicillin | Amoxicillin | 61 | 53 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | suppressed |
| Celecoxib | Celecoxib | 59 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 58 | 38 |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 57 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 57 | 20 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 19 |
| Aripiprazole | Aripiprazole | 54 | 13 |
| Warfarin Sodium | Warfarin Sodium | 54 | suppressed |
| Primidone | Primidone | 53 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 21 |
| Sucralfate | Sucralfate | 53 | 18 |
| Tramadol Hcl | Tramadol Hcl | 52 | 29 |
| Myrbetriq | Mirabegron | 51 | 12 |
| Spironolactone | Spironolactone | 51 | 19 |
| Atenolol | Atenolol | 50 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | 12 |
| Memantine Hcl | Memantine Hcl | 49 | 13 |
| Topiramate | Topiramate | 49 | 14 |
| Methylprednisolone | Methylprednisolone | 47 | 44 |
| Baclofen | Baclofen | 46 | 20 |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 46 | 12 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 45 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 14 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 43 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 13 |
| Clonidine Hcl | Clonidine Hcl | 42 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Mupirocin | Mupirocin | 42 | 33 |
| Benazepril Hcl | Benazepril Hcl | 41 | 13 |
| Lorazepam | Lorazepam | 41 | 11 |
| Mirtazapine | Mirtazapine | 41 | 15 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | 12 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 40 | 40 |
| Azithromycin | Azithromycin | 40 | 39 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 18 |
| Estradiol | Estradiol | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 33 |
| Fluconazole | Fluconazole | 38 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 38 | 28 |
| Nortriptyline Hcl | Nortriptyline Hcl | 37 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 17 |
| Promethazine Hcl | Promethazine Hcl | 36 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 14 |
| Repatha Sureclick | Evolocumab | 34 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | 12 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 31 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 14 |
| Levetiracetam | Levetiracetam | 31 | 12 |
| Novolog Flexpen | Insulin Aspart | 31 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | 13 |
| Insulin Lispro | Insulin Lispro | 30 | 11 |
| Ondansetron Odt | Ondansetron | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | 11 |
| Torsemide | Torsemide | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Colchicine | Colchicine | 26 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | 12 |
| Valsartan | Valsartan | 25 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | 19 |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Novolog | Insulin Aspart | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 16 | 16 |
| Digoxin | Digoxin | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 14 |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 12 |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | 12 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 12 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Risperdal Consta | Risperidone Microspheres | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,818.08 · 84 records | Corcept Therapeutics | ACCRUFER, AFREZZA, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, Fluad, Flucelvax, GVOKE HYPOPEN, JOURNAVX, Kerendia, Korlym, LEQVIO, MOUNJARO, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, Quviviq, REPATHA, Rybelsus, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, VRAYLAR, VYEPTI, WATCHMAN Access System, Wegovy, XIFAXAN, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error